PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.07%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
822.03%
Gross profit growth at 50-75% of CRON.TO's 1117.09%. Martin Whitman would question if cost structure or brand is lagging.
-112.41%
Negative EBIT growth while CRON.TO is at 56.55%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-112.41%
Negative operating income growth while CRON.TO is at 25.99%. Joel Greenblatt would press for urgent turnaround measures.
85.63%
Net income growth 1.25-1.5x CRON.TO's 75.58%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
86.67%
EPS growth 1.25-1.5x CRON.TO's 75.90%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
87.78%
Diluted EPS growth 1.25-1.5x CRON.TO's 75.90%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
11.12%
Share count expansion well above CRON.TO's 1.06%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
13.10%
Diluted share count expanding well above CRON.TO's 0.67%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-125.44%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-88.64%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
549.91%
5Y revenue/share CAGR above 1.5x CRON.TO's 264.48%. David Dodd would look for consistent product or market expansions fueling outperformance.
-39.53%
Negative 3Y CAGR while CRON.TO stands at 118.93%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-3850.87%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-216.02%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
25.36%
Positive 3Y OCF/share CAGR while CRON.TO is negative. John Neff might see a big short-term edge in operational efficiency.
-2957.33%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-213.57%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-299.18%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
7956.19%
10Y equity/share CAGR above 1.5x CRON.TO's 1439.44%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
304.44%
5Y equity/share CAGR at 75-90% of CRON.TO's 358.35%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
30.41%
Positive short-term equity growth while CRON.TO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.22%
Our AR growth while CRON.TO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-0.36%
Inventory is declining while CRON.TO stands at 17.86%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
2.62%
Positive asset growth while CRON.TO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-7.54%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
5.45%
We have some new debt while CRON.TO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
207.41%
We increase R&D while CRON.TO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-7.22%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.